Brightside Health Raises $50M for Personalized Anxiety & Depression Care

Brightside Health Raises $50M for Personalized Anxiety & Depression Care

What You Should Know:

– Today, Brightside Health announced it raised a $50M Series B, led by ACME Capital and Mousse Partners, bringing its total funding to $75M to date.

– The funding will help Brightside expand access to high-quality mental healthcare to more people across the country, enhance the platform, forge new partnerships, and grow as a team, from about 57 now to an expected 175 later this year. 


Brightside Health, a telemedicine platform that offers fast access to personalized treatment, expert providers, and ongoing support for a range of mental health concerns raises $50 million in Series B funding to address the unmet need of quality mental health care for all. This round, led by ACME Capital and Mousse Partners, with participation from existing investors Bullpen Capital, Triventures, and Trousdale Ventures, brings Brightside Health’s total funding to date to $75 million.

Expert Care to Overcome Your Anxiety & Depression

Founded in 2017, Brightside offers its anxiety and depression care through Cigna and recently partnered with Aetna, now giving 30M insurance members nationwide access to Brightside’s care. Brightside Health treats the full spectrum of symptom severity, including people with complex conditions, and offers timely appointments from home, available in as little as 24 hours. With convenient access to treatment through video visits, unlimited messaging, ongoing support, and medication delivery, Brightside Health helps people feel better faster, and stay that way longer.

The platform adheres to evidence-based approaches, guided by a world-class network of psychiatric providers and licensed therapists who utilize innovative support tools and follow structured, clinically-proven protocols to deliver effective care at scale. Members track progress through online check-ins that are also monitored by providers, ensuring the efficacy of personalized treatment plans and enabling rapid intervention should a need arise.

Outcomes/Results

After an intake assessment, Brightside Health leverages a proprietary machine-learning algorithm to evaluate more than 100 data points about an individual to efficiently assist providers in tailoring treatment to each person—enabling the company to deliver effective personalized care and industry-leading results. In a recent study, Brightside Health delivered over 50% higher treatment response and remission rates than a leading U.S. health system. Currently, 86% of Brightside Health’s patients experience clinically significant improvement, and 71% achieve remission levels, within their first 12 weeks of treatment.

“The Brightside model of combining data, technology, and clinicians is changing mental health outcomes, with 86% of our members feeling better within the first 12 weeks,” said Brad Kittredge, founder and CEO of Brightside Health. “Our goal is to achieve 100%, with improvement among all members. This new capital will help us grow our team from 57 to an expected 175 employees this year, and further enhance our platform and partnerships to expand access to more individuals. Because we stand behind the quality and accountability of our care model, we are happy to put our dollars behind delivering the best possible outcomes and open up the path to true value-based care in mental health. Together, we can treat depression and anxiety in an approachable, affordable way and positively change lives.”